Bruce Eaton is the president and chief executive officer of Velocity Sciences, a leader in the diagnostics services industry. He also serves as the president and chief executive officer of i2 Pharmaceuticals, Inc., where he has expanded the company’s intellectual property holdings and formed strategic partnerships with some of the biggest names in the pharmaceutical space.
Earlier in his career, Bruce Eaton served as the vice president of chemistry at NeXstar Pharmaceuticals, where he oversaw a team of 50 scientists tasked with producing the company’s first successful aptamer IND. The product, now known by its trade name Macugen, was acquired by Pfizer and marketed as a treatment for age-related macular degeneration. Dr. Eaton also spent time as the president of Invenux, which he co-founded, where he used small molecule libraries to generate drug discovery leads in a highly efficient manner. After securing a series A financing round of $8 million, he created a scientific advisory board with members such as Oxford’s Steve Davies and Bill Roush of Scripps FL.
Over the course of his career in biotechnology and medicinal chemistry, Bruce Eaton has published articles in journals such as Nature, and the Journal of the American Chemical Society. In particular, he has focused his research on organic methods development, organometallic catalysis, and nucleic acid chemistry. Dr. Eaton holds a Ph.D. from the University of California at Berkeley.